SynthesisTransplant infectious disease : an official journal of the Transplantation Society
Human Herpesvirus 8 Causes a Wide Spectrum of Disease in Liver Transplant Recipients and May be Donor Derived: Case Series and Systematic Review of an Emerging Challenge.
Synthesis in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman herpesvirus 8 (HHV8), also known as Kaposi sarcoma (KS)-associated herpesvirus, can cause severe disease in liver transplant (LT) recipients, be donor-derived, and present variably. We describe HHV8 disease post-LT.
methodsHHV8 disease was identified post-LT in New South Wales (NSW), 2017-2024, and from systematic review. Reports were compared by suspected donor-derived infection (DDI) and disease manifestation, using chi-square and t-tests. Survival was investigated with Cox proportional hazards.
resultsOf 188 records, 79 publications (131 cases) were included, plus four NSW cases (n = 135). Median onset was 7 months posttransplant (IQR: 5-13), with 33% suspected DDI. After median 12 months of follow-up, 68/125 had disease remission/regression; 59/135 died (49 HHV8-related). In NSW, Case 1 was proven DDI: visceral KS, 6 months post-LT; complete remission occurred with immunosuppression modification and chemotherapy. Case 2 was probable DDI: KS, multicentric Castleman's disease, and hemophagocytic lymphohistiocytosis, 3 months post-LT; the patient died despite immunosuppression modification, hydrocortisone and rituximab. Case 3 was possible DDI: KS-herpesvirus-induced cytokine syndrome, 6 months post-LT; died despite immunosuppression modification and ganciclovir. Case 4 was unlikely DDI: visceral KS, 5 months post-LT; complete remission occurred with surgery and immunosuppression modification. Survival was worse with visceral KS and non-KS disease (aHR 5.83 and 4.32, p = 0.002). Reduced immunosuppression, mTORi, and chemotherapy improved survival (aHRs 0.53, 0.36, 0.43; p = 0.006, 0.044, and 0.030). Treatment effects diverged by KS and non-KS disease. Donor screening identified more KICS and DDI, with improved non-KS disease survival.
conclusionPost-LT HHV8 disease is heterogeneous, with high mortality. Targeted treatments and possibly donor screening improve survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.